BostonGene, a leader in AI-powered solutions for drug discovery and development, is transforming how pharmaceutical companies develop, target, and deliver cancer therapies — making precision medicine a reality at scale.
Today, bringing a new cancer drug to market takes an average of 10.5 years, costs more than $2.5 billion, and succeeds only 8% of the time. BostonGene is changing that reality. Powered by advanced AI and multiomic analysis — integrating molecular and immune system data — BostonGene accelerates development, identifies high-value therapies and matches them to the patients most likely to respond.
Outsmarting cancer’s complexity with a digital twin of each patient
In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s AI platform combines multiomic profiling — integrating DNA and RNA sequencing, immune system profiling, and tissue architecture to deliver a complete biological portrait of each tumor and its microenvironment.
BostonGene turns blood into a full biological blueprint — matching tissue-level insight without the need for an invasive biopsy. This supports continuous monitoring and the creation of a “digital twin” — a dynamic model of each patient’s disease and likely treatment responses.
This multidimensional view uncovers patterns and relationships traditional approaches miss — sharpening drug targeting, optimizing trial design, and driving faster, more predictable success.
Unlocking new indications and new markets
BostonGene’s proprietary AI models, trained on billions of human biology data points, identify cancers that express a drug’s target and flag potential off-target risks in healthy tissues. The platform benchmarks candidate therapies against the current standard of care, leveraging a curated integration of real-world clinical data, internal lab analytics, and peer-reviewed scientific literature.
Underpinned by foundation models trained across vast molecular and clinical datasets, BostonGene delivers scalable insights into rare and complex cases, bringing data-driven clarity to development decisions.
This data-driven approach enables pharma companies to prioritize indications, avoid costly failures, and accelerate time to market.
Designing smarter, stronger combination therapies
Effective combination therapies are transforming cancer care, but identifying the right combinations requires deep biologic insight. BostonGene’s AI models predict therapeutic responses and help partners design combination strategies, pairing targeted therapies like antibody-drug conjugates with immunotherapies.
This precision guidance improves trial efficiency, raises success rates, and accelerates the delivery of more effective treatment options to patients.
Delivering results — with foundation model intelligence and real-world impact
BostonGene’s platform is already transforming development pipelines. Its insights have validated novel targets, stratified patient populations, and uncovered new uses for existing therapies. By building on foundational models, digital twins, and immune system profiling, BostonGene helps pharmaceutical companies de-risk programs, reduce patient burden, and accelerate clinical timelines.
With deep biological intelligence, powerful AI, and a proven track record, BostonGene empowers pharma innovators to move smarter, faster, and with greater certainty into the future of cancer care.
To learn more, visit bostongene.com
